Acute myocardial infarction leads to acceleration of atherosclerosis

Atherosclerosis

Volumn 229, Issue 1, 2013, Pages 18-22

  Wang, Hui ^a   Eitzman, Daniel T ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Inflammatory cytokines; Leukocytes; Recurrent myocardial infarction

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CCAAT ENHANCER BINDING PROTEIN DELTA; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARINOID; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED PROTEIN 3; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADAPTIVE IMMUNITY; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE COURSE; HEART REINFARCTION; HUMAN; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE ACTIVATION; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ATHEROSCLEROSIS; DISEASE PROGRESSION; HUMANS; MYOCARDIAL INFARCTION; RISK FACTORS; VASCULITIS;

EID: 84879415477     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.04.004     Document Type: Review

References (47)

1. Gersh B.J., Sliwa K., Mayosi B.M., Yusuf S. Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. Eur Heart J 2010, 31:642-648.
2. Viles-Gonzalez J.F., Fuster V., Badimon J.J. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004, 25:1197-1207.
3. Hansson G.K. Inflammatory mechanisms in atherosclerosis. JThromb Haemost 2009, 7(Suppl. 1):328-331.
4. Young J.L., Libby P., Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002, 88:554-567.
5. MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
6. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. NEngl J Med 2004, 350:1495-1504.
7. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080.
8. Waters D.D., Guyton J.R., Herrington D.M., McGowan M.P., Wenger N.K., Shear C. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am J Cardiol 2004, 93:154-158.
9. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012, 32:2045-2051.
10. Tuttolomondo A., Di Raimondo D., Pecoraro R., Arnao V., Pinto A., Licata G. Atherosclerosis as an inflammatory disease. Curr Pharm Des 2012, 18:4266-4288.
11. Thune J.J., Signorovitch J.E., Kober L., et al. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. Eur J Heart Fail 2011, 13:148-153.
12. Pfeffer M.A., McMurray J., Leizorovicz A., et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000, 140:727-750.
13. Jokhadar M., Jacobsen S.J., Reeder G.S., Weston S.A., Roger V.L. Sudden death and recurrent ischemic events after myocardial infarction in the community. Am J Epidemiol 2004, 159:1040-1046.
14. Rosamond W.D., Chambless L.E., Folsom A.R., et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. NEngl J Med 1998, 339:861-867.
15. Ridker P.M., Rifai N., Pfeffer M., Sacks F., Lepage S., Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000, 101:2149-2153.
16. Ridker P.M., Rifai N., Pfeffer M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) investigators. Circulation 1998, 98:839-844.
17. Gonzalez-Quesada C., Frangogiannis N.G. Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes. Curr Atheroscler Rep 2009, 11:131-138.
18. de Jager S.C., Bongaerts B.W., Weber M., et al. Chemokines CCL3/MIP1alpha, CCL5/RANTES and CCL18/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes. PLoS One 2012, 7:e45804.
19. Zernecke A., Bernhagen J., Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation 2008, 117:1594-1602.
20. Yi W., Sun Y., Yuan Y., et al. C1q/tumor necrosis factor-related protein-3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heart. Circulation 2012, 125:3159-3169.
21. Orn S., Breland U.M., Mollnes T.E., et al. The chemokine network in relation to infarct size and left ventricular remodeling following acute myocardial infarction. Am J Cardiol 2009, 104:1179-1183.
22. Ono K., Matsumori A., Shioi T., Furukawa Y., Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998, 98:149-156.
23. Takaoka M., Uemura S., Kawata H., et al. Inflammatory response to acute myocardial infarction augments neointimal hyperplasia after vascular injury in a remote artery. Arterioscler Thromb Vasc Biol 2006, 26:2083-2089.
24. Liu Y., Imanishi T., Ikejima H., et al. Association between circulating monocyte subsets and in-stent restenosis after coronary stent implantation in patients with ST-elevation myocardial infarction. Circ J 2010, 74:2585-2591.
25. Wright A.P., Ohman M.K., Hayasaki T., et al. Atherosclerosis and leukocyte-endothelial adhesive interactions are increased following acute myocardial infarction in apolipoprotein E deficient mice. Atherosclerosis 2010, 212:414-417.
26. Dutta P., Courties G., Wei Y., et al. Myocardial infarction accelerates atherosclerosis. Nature 2012, 487:325-329.
27. Katayama Y., Battista M., Kao W.M., et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 2006, 124:407-421.
28. Smith S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113:2363-2372.
29. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86.
30. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366:1607-1621.
31. LaRosa J.C., Deedwania P.C., Shepherd J., et al. Comparison of 80 versus 10mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol 2010, 105:283-287.
32. Tikkanen M.J., Szarek M., Fayyad R., et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. JAm Coll Cardiol 2009, 54:2353-2357.
33. Murphy S.A., Cannon C.P., Wiviott S.D., McCabe CH., Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22) trial. JAm Coll Cardiol 2009, 54:2358-2362.
34. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286:64-70.
35. Oliver M.F. Control of free fatty acids during acute myocardial ischaemia. Heart 2010, 96:1883-1884.
36. Freemantle N., Cleland J., Young P., Mason J., Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999, 318:1730-1737.
37. Chen Z.M., Pan H.C., Chen Y.P., et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366:1622-1632.
38. Croft K.D., Dimmitt S.B., Moulton C., Beilin L.J. Low density lipoprotein composition and oxidizability in coronary disease - apparent favourable effect of beta blockers. Atherosclerosis 1992, 97:123-130.
39. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008, 122:743-752.
40. Yusuf S., Pepine C.J., Garces C., et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992, 340:1173-1178.
41. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. NEngl J Med 1992, 327:669-677.
42. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. NEngl J Med 2003, 348:1309-1321.
43. Goldstein J.A., Demetriou D., Grines C.L., Pica M., Shoukfeh M., O'Neill W.W. Multiple complex coronary plaques in patients with acute myocardial infarction. NEngl J Med 2000, 343:915-922.
44. Tanaka A., Shimada K., Sano T., et al. Multiple plaque rupture and C-reactive protein in acute myocardial infarction. JAm Coll Cardiol 2005, 45:1594-1599.
45. Antman E.M., Tanasijevic M.J., Thompson B., et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. NEngl J Med 1996, 335:1342-1349.
46. Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011, 162:597-605.
47. Ridker P.M. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). JThromb Haemost 2009, 7(Suppl. 1):332-339.